Loading insider details...
Beta
Latest Form 4 (Oct 5, 2026): Exercise/Conversion of 13,000 ELVN shares, $201.1K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Enliven Therapeutics, Inc. (ELVN) | Exercise/Conversion | 13,000 | $201.1K |
| Jun 23, 2026 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/Award | 29,500 | n/a |
| Jun 5, 2026 | LB PHARMACEUTICALS INC (LBRX) | Grant/Award | 10,000 | n/a |
| Apr 23, 2026 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to Issuer | 48,072 | n/a |
| Feb 18, 2026 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 1,427 | n/a |
| Jan 21, 2026 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/Award | 40,400 | n/a |
| Jan 9, 2026 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 59,372 | n/a |
| Nov 7, 2025 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to Issuer | 48,072 | n/a |
| Sep 12, 2025 | LB PHARMACEUTICALS INC (LBRX) | Disposition to Issuer | 17,929 | n/a |
| Jun 13, 2025 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/Award | 24,150 | n/a |